Galapagos increases share capital through warrant exercises
17 Marzo 2020 - 9:01PM
Mechelen, Belgium; 17 March 2020, 21.01 CET; regulated
information – Galapagos NV (Euronext & NASDAQ: GLPG) announces
a share capital increase arising from warrant exercises.
Galapagos issued 152,220 new ordinary shares on 17 March 2020,
for a total capital increase (including issuance premium) of
€5,354,538.80.
Pursuant to the warrant exercise program of
Galapagos’ executive committee, executive committee members
automatically are committed to exercise a minimum number of
warrants, subject to certain conditions. In accordance with the
rules of this program, CEO Onno van de Stolpe exercised 15,000
warrants. Three other executive committee members exercised an
aggregate number of 15,000 warrants. In addition, two members of
the board of directors exercised an aggregate number of 17,520
warrants.
In accordance with Belgian transparency
legislation1, Galapagos notes that its total share capital
currently amounts to €350,612,693.52, the total number of
securities conferring voting rights is 64,819,022, which is also
the total number of voting rights (the “denominator”), and all
securities conferring voting rights and all voting rights are of
the same category. The total number of rights (warrants) to
subscribe to not yet issued securities conferring voting rights is
(i) 5,386,697 warrants under several outstanding employee warrant
plans, which equals 5,386,697 voting rights that may result from
the exercise of those warrants, and (ii) two warrants issued to
Gilead Therapeutics to subscribe for a maximum number of shares
that is sufficient to bring the shareholding of Gilead and its
affiliates to 25.1% and 29.9%, respectively, of the actually issued
and outstanding shares after the exercise of the relevant warrant.
Galapagos does not have any convertible bonds or shares without
voting rights outstanding.
About GalapagosGalapagos (Euronext &
NASDAQ: GLPG) discovers and develops small molecule medicines with
novel modes of action, three of which show promising patient
results and are currently in late-stage development in multiple
diseases. Our pipeline comprises Phase 3 through to discovery
programs in inflammation, fibrosis, osteoarthritis and other
indications. Our ambition is to become a leading global
biopharmaceutical company focused on the discovery, development and
commercialization of innovative medicines. More information at
www.glpg.com.
Contacts
Investors:Elizabeth GoodwinVP Investor Relations +1 781
460 1784
Sofie Van GijselDirector Investor Relations+32 485 19 14
15ir@glpg.com
Media:Carmen VroonenSenior Director Communications &
Public Affairs+32 473 824 874
Evelyn FoxDirector Communications +31 6 53 591 999
communications@glpg.com
Forward-looking statements
This release may contain forward-looking
statements. Such forward-looking statements are not guarantees of
future results. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any forward-looking statements
in this document, unless specifically required by law or
regulation.
1 Belgian Act of 2 May 2007 on the disclosure of
major shareholdings in issuers whose shares are admitted to trading
on a regulated market
Grafico Azioni Galapagos (EU:GLPG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Galapagos (EU:GLPG)
Storico
Da Apr 2023 a Apr 2024